Correction to: 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
暂无分享,去创建一个
Hugh Calkins | L. Chen | M. Ezekowitz | K. Furie | H. Calkins | C. January | L. Wann | J. Cigarroa | J. Cleveland | P. Ellinor | M. Field | K. Murray | C. Tracy | C. Yancy | L. Fleisher | B. Riegel | B. Bozkurt | J. Beckman | G. Levine | P. Heidenreich | P. O'Gara | Z. Goldberger | M. Hlatky | L. Mauri | L. Curtis | R. Brindis | S. Pressler | J. Shea | J. Ikonomidis | K. Birtcher | J. Joglar | D. Wijeysundera | Clyde W Yancy | Michael D Ezekowitz | Craig T January | Lin Y Chen | L Samuel Wann | Joaquin E Cigarroa | Joseph C Cleveland | Patrick T Ellinor | Michael E Field | Katherine T Murray | Cynthia M Tracy | Karen L Furie | Paul A Heidenreich | Julie B Shea | A. Deswal | Federico Gentile | S. Gidding
[1] V. Aboyans,et al. Female sex as a risk factor for ischaemic stroke varies with age in patients with atrial fibrillation , 2019, Heart.
[2] Correction to: Outcomes Associated with Apixaban Use in End-Stage Kidney Disease Patients with Atrial Fibrillation in the United States. , 2018, Circulation.
[3] P. Noseworthy,et al. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States , 2018, Circulation.
[4] S. Yusuf,et al. Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. , 2018, Journal of the American College of Cardiology.
[5] R. Mahajan,et al. PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study , 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[6] B. Lindsay,et al. Smartwatch Algorithm for Automated Detection of Atrial Fibrillation. , 2018, Journal of the American College of Cardiology.
[7] P. Kirchhof,et al. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial , 2018, European heart journal.
[8] H. Maitland,et al. Safety and effectiveness of apixaban compared to warfarin in dialysis patients , 2018, Research and practice in thrombosis and haemostasis.
[9] R. de Caterina,et al. Digoxin and Mortality in Patients With Atrial Fibrillation. , 2018, Journal of the American College of Cardiology.
[10] D. Mark,et al. Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design , 2018, American heart journal.
[11] G. Lip,et al. Prediction of long‐term net clinical outcomes using the TIMI‐AF score: Comparison with CHA2DS2‐VASc and HAS‐BLED , 2018, American heart journal.
[12] G. Lip,et al. Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA2DS2-VA Score Rather Than CHA2DS2-VASc? , 2018, Circulation.
[13] L. Jordaens,et al. Catheter Ablation for Atrial Fibrillation with Heart Failure , 2018, The New England journal of medicine.
[14] J. Piccini,et al. Association Between Left Atrial Appendage Occlusion and Readmission for Thromboembolism Among Patients With Atrial Fibrillation Undergoing Concomitant Cardiac Surgery , 2018, JAMA.
[15] P. Noseworthy,et al. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. , 2017, Journal of the American College of Cardiology.
[16] Michael B. Gravenor,et al. Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study , 2017, Circulation.
[17] G. Lip,et al. Meta-Analysis of Effectiveness and Safety of Oral Anticoagulants in Atrial Fibrillation With Focus on Apixaban. , 2017, The American journal of cardiology.
[18] S. Prabhu,et al. Catheter Ablation Versus Medical Rate control in Atrial Fibrillation and Systolic Dysfunction (CAMERA-MRI) , 2017 .
[19] A. Ferro,et al. Indications for anticoagulant and antiplatelet combined therapy , 2017, British Medical Journal.
[20] S. Kische,et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. , 2017, Heart rhythm.
[21] Deepak L. Bhatt,et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation , 2017, The New England journal of medicine.
[22] T. Steiner,et al. Idarucizumab for Dabigatran Reversal — Full Cohort Analysis , 2017, The New England journal of medicine.
[23] J. Saw,et al. The Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) trial. , 2017, American heart journal.
[24] T. Mavrakanas,et al. Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. , 2017, Journal of the American Society of Nephrology : JASN.
[25] D. Singer,et al. Effects of Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta‐Analysis , 2017, Journal of the American Heart Association.
[26] L. Fleisher,et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2017, Journal of the American College of Cardiology.
[27] J. Hartikainen,et al. Sex, age, and time to cardioversion. Risk factors for cardioversion of acute atrial fibrillation from the FinCV study , 2017, Annals of medicine.
[28] P. Noseworthy,et al. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study. , 2017, Gastroenterology.
[29] K. Tellor,et al. Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment , 2017, Pharmacotherapy.
[30] C. Siu,et al. Association Between Dabigatran vs Warfarin and Risk of Osteoporotic Fractures Among Patients With Nonvalvular Atrial Fibrillation , 2017, JAMA.
[31] D. Adams. Idarucizumab for Dabigatran Reversal Full Cohort Analysis , 2017 .
[32] S. Hohnloser,et al. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation , 2017, The New England journal of medicine.
[33] R. de Caterina,et al. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. , 2017, Circulation.
[34] J. Seward,et al. Impact of Left Atrial Appendage Closure During Cardiac Surgery on the Occurrence of Early Postoperative Atrial Fibrillation, Stroke, and Mortality: A Propensity Score–Matched Analysis of 10 633 Patients , 2017, Circulation.
[35] W. O’Neill,et al. Post-Approval U.S. Experience With Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation. , 2017, Journal of the American College of Cardiology.
[36] D. Singer,et al. Wide Variation in Reported Rates of Stroke Across Cohorts of Patients With Atrial Fibrillation , 2017, Circulation.
[37] E. Antman,et al. A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial , 2017, European heart journal.
[38] Christopher X. Wong,et al. Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical implications, and future directions , 2016, European heart journal.
[39] G. Lip,et al. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis , 2017, Stroke.
[40] P. Noseworthy,et al. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. , 2016, Chest.
[41] G. Lip,et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. , 2016, The New England journal of medicine.
[42] Ya-Hui Hsueh,et al. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. , 2016, JAMA internal medicine.
[43] G. Lip,et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin , 2016, Thrombosis and Haemostasis.
[44] G. Lip,et al. Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial , 2016, The Lancet.
[45] L. Fauchier,et al. Evaluation of 5 Prognostic Scores for Prediction of Stroke, Thromboembolic and Coronary Events, All-Cause Mortality, and Major Adverse Cardiac Events in Patients With Atrial Fibrillation and Coronary Stenting. , 2016, The American journal of cardiology.
[46] S. Connolly,et al. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. , 2016, The New England journal of medicine.
[47] S. Yusuf,et al. Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). , 2016, Circulation.
[48] M. Chung,et al. Incidence of Thromboembolic Complications Within 30 Days of Electrical Cardioversion Performed Within 48 Hours of Atrial Fibrillation Onset. , 2016, JACC. Clinical electrophysiology.
[49] L. Räber,et al. Duration of Triple Antithrombotic Therapy and Outcomes Among Patients Undergoing Percutaneous Coronary Intervention. , 2016, JACC. Cardiovascular interventions.
[50] L. Fauchier,et al. Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated? , 2016, Stroke.
[51] G. Lip,et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study , 2016, British Medical Journal.
[52] R. de Caterina,et al. Cardioversion of Atrial Fibrillation in ENGAGE AF‐TIMI 48 , 2016, Clinical cardiology.
[53] A. Phrommintikul,et al. Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis , 2016, Open Heart.
[54] P. Noseworthy,et al. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation , 2016, Journal of the American Heart Association.
[55] C. Frost,et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis , 2016, Journal of clinical pharmacology.
[56] Dhanunjaya R. Lakkireddy,et al. Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial , 2016, Circulation.
[57] William Smith,et al. Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis , 2016, American Journal of Nephrology.
[58] J. Cigarroa,et al. Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, Circulation.
[59] L. Biase. Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions , 2016 .
[60] L. Di Biase. Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions , 2016, Journal of the American Heart Association.
[61] S. Kische,et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry , 2016, European heart journal.
[62] L. Fauchier,et al. CHA2DS2-VASc Score for Predicting Stroke and Thromboembolism in Patients With AF and Biological Valve Prosthesis. , 2016, Journal of the American College of Cardiology.
[63] S. Daher,et al. The Complex Role of Anticoagulation in Cirrhosis: An Updated Review of Where We Are and Where We Are Going , 2016, Digestion.
[64] E. Antman,et al. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial , 2015, Circulation.
[65] J. Cigarroa,et al. Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, Journal of the American College of Cardiology.
[66] M. Price,et al. Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial Experience. , 2015, JACC. Cardiovascular interventions.
[67] J. Messenger,et al. Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. , 2015, JACC. Cardiovascular interventions.
[68] S. Connolly,et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. , 2015, The New England journal of medicine.
[69] Á. Avezum,et al. Abstract 17277: Apixaban Use in Patients With Atrial Fibrillation With Bioprosthetic Valves: Insights From ARISTOTLE , 2015 .
[70] A. Schjerning,et al. Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin—A Nationwide Cohort Study , 2015, PloS one.
[71] V. Hasselblad,et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. , 2015, The New England journal of medicine.
[72] S. Hohnloser,et al. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. , 2015, European heart journal.
[73] G. Lip,et al. Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. , 2015, European heart journal.
[74] D. De Bacquer,et al. Dose-finding study of rivaroxaban in hemodialysis patients. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[75] Saibal Kar,et al. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. , 2015, Journal of the American College of Cardiology.
[76] M. Chung,et al. Catheter Ablation for Atrial Fibrillation in Heart Failure Patients: A Meta-Analysis of Randomized Controlled Trials. , 2015, JACC. Clinical electrophysiology.
[77] Christopher X. Wong,et al. Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY). , 2015, Journal of the American College of Cardiology.
[78] H. Schunkert,et al. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. , 2015, Journal of the American College of Cardiology.
[79] M. Gianni,et al. Efficacy and safety of direct oral anticoagulants in patients undergoing cardioversion for atrial fibrillation: A systematic review and meta-analysis of the literature. , 2015, International journal of cardiology.
[80] E. Edelman,et al. Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis , 2015, Circulation.
[81] S. Koul,et al. Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. , 2015, Thrombosis research.
[82] M. Lamberts,et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. , 2014, Journal of the American College of Cardiology.
[83] A. Camm,et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. , 2014, European heart journal.
[84] R. Mahajan,et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. , 2014, Journal of the American College of Cardiology.
[85] M. Ezekowitz,et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.
[86] G. Lip,et al. Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. , 2014, QJM : monthly journal of the Association of Physicians.
[87] S. Raposeiras-Roubín,et al. Is 6-month GRACE risk score a useful tool to predict stroke after an acute coronary syndrome? , 2014, Open Heart.
[88] Saibal Kar,et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. , 2014, JAMA.
[89] I. Bryngelsson,et al. Gender-related differences in risk of cardiovascular morbidity and all-cause mortality in patients hospitalized with incident atrial fibrillation without concomitant diseases: a nationwide cohort study of 9519 patients. , 2014, International journal of cardiology.
[90] Eli N. Deal,et al. Apixaban Use Among Patients With Severe Renal Impairment , 2014, The Annals of pharmacotherapy.
[91] Donna K Arnett,et al. AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and U.S. Department of Health and Human Services. , 2014, Journal of the American College of Cardiology.
[92] Richard A. Goodman,et al. AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and US Department of Health and Human Services. , 2014, Circulation.
[93] Jeffrey L. Anderson,et al. The Evolution and Future of ACC/AHA Clinical Practice Guidelines: A 30-Year Journey A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.
[94] J. Hartikainen,et al. Time to cardioversion for acute atrial fibrillation and thromboembolic complications. , 2014, JAMA.
[95] M. Price,et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. , 2014, Journal of the American College of Cardiology.
[96] Frank Beckers,et al. Cryptogenic stroke and underlying atrial fibrillation. , 2014, The New England journal of medicine.
[97] Thoralf M Sundt,et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.
[98] Thoralf M Sundt,et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[99] G. Fonarow,et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. , 2014, Circulation.
[100] P. Kirchhof,et al. One‐Year Outcome of Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting: An Analysis of the AFCAS Registry , 2014, Clinical cardiology.
[101] Chad Hughes,et al. Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. , 2014, The Journal of thoracic and cardiovascular surgery.
[102] Jun Zhu,et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). , 2014, Journal of the American College of Cardiology.
[103] Alexander Parkhomenko,et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.
[104] F. Marchlinski,et al. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. , 2014, The American journal of cardiology.
[105] Daniel E. Singer,et al. Device-detected atrial fibrillation and risk for stroke: an analysis of >10 000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices) , 2013, European heart journal.
[106] Hugh Calkins,et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.
[107] L. Shaw,et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.
[108] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[109] W. Abhayaratna,et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. , 2013, JAMA.
[110] S. Connolly,et al. Dabigatran versus warfarin in patients with mechanical heart valves. , 2013, The New England journal of medicine.
[111] J. Hartikainen,et al. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. , 2013, Journal of the American College of Cardiology.
[112] L. Køber,et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. , 2013, Journal of the American College of Cardiology.
[113] Petr Neuzil,et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). , 2013, Journal of the American College of Cardiology.
[114] A. Kastrati,et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. , 2013, Journal of the American College of Cardiology.
[115] G. Breithardt,et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. , 2013, Journal of the American College of Cardiology.
[116] Tom Adriaenssens,et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial , 2013, The Lancet.
[117] Deepak L. Bhatt,et al. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[118] Deepak L. Bhatt,et al. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[119] PubMed Id. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013 .
[120] Yuan Zhang,et al. Obesity results in progressive atrial structural and electrical remodeling: implications for atrial fibrillation. , 2013, Heart rhythm.
[121] Gregory Y H Lip,et al. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation , 2012, Expert review of cardiovascular therapy.
[122] A. Brand,et al. Is female sex a risk factor for red blood cell alloimmunization after transfusion? A systematic review. , 2012, Transfusion medicine reviews.
[123] J. Olesen,et al. Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study , 2012, Journal of thrombosis and haemostasis : JTH.
[124] T. Lehr,et al. Dabigatran Etexilate in Atrial Fibrillation Patients With Severe Renal Impairment: Dose Identification Using Pharmacokinetic Modeling and Simulation , 2012, Journal of clinical pharmacology.
[125] Habib Gamra,et al. Distribution and Risk Profile of Paroxysmal, Persistent, and Permanent Atrial Fibrillation in Routine Clinical Practice: Insight From the Real-Life Global Survey Evaluating Patients With Atrial Fibrillation International Registry , 2012, Circulation. Arrhythmia and electrophysiology.
[126] S. Connolly,et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). , 2012, American heart journal.
[127] D. Lake,et al. Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation. , 2012, The American journal of medicine.
[128] J. Olesen,et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: A nationwide cohort study , 2012, Thrombosis and Haemostasis.
[129] Salim Yusuf,et al. Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study. , 2012, Journal of the American College of Cardiology.
[130] D. Singer,et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.
[131] A. Capucci,et al. Subclinical atrial fibrillation and the risk of stroke. , 2012, The New England journal of medicine.
[132] S. Hariharan,et al. Clinical Pharmacology Basis of Deriving Dosing Recommendations for Dabigatran in Patients With Severe Renal Impairment , 2012, Journal of clinical pharmacology.
[133] Shigeto Miura,et al. [Hemodialysis patients]. , 2012, Nihon rinsho. Japanese journal of clinical medicine.
[134] A. Mills,et al. Is discharge to home after emergency department cardioversion safe for the treatment of recent-onset atrial fibrillation? , 2011, Annals of emergency medicine.
[135] W. Winkelmayer,et al. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[136] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[137] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[138] Prashanthan Sanders,et al. Pericardial fat is associated with atrial fibrillation severity and ablation outcome. , 2011, Journal of the American College of Cardiology.
[139] Jun Zhu,et al. Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[140] S. Yusuf,et al. Dabigatran Versus Warfarin in Patients With Atrial Fibrillation: An Analysis of Patients Undergoing Cardioversion , 2010, Circulation.
[141] S. Greenfield,et al. Clinical practice guidelines we can trust , 2011 .
[142] Laura A. Levit,et al. Finding what works in health care : standards for systematic reviews , 2011 .
[143] Gregory Y H Lip,et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.
[144] P. Lavori,et al. Effect of home testing of international normalized ratio on clinical events. , 2010, The New England journal of medicine.
[145] Gregory Y H Lip,et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.
[146] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[147] S. Schneider,et al. Prevalence of left atrial thrombus and dense spontaneous echo contrast in patients with short-term atrial fibrillation < 48 hours undergoing cardioversion: value of transesophageal echocardiography to guide cardioversion. , 2009, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[148] P. Komenda,et al. The intersection of risk and benefit: is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis? , 2009, Chest.
[149] Dongfeng Qi,et al. The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study , 2009, Circulation. Arrhythmia and electrophysiology.
[150] Salim Yusuf,et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[151] Jacky Serveille,et al. [Ablation of atrial fibrillation]. , 2008, Soins; la revue de reference infirmiere.
[152] Eva Navas,et al. Accepted Manuscript , 2022 .
[153] M. Aguilar,et al. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.
[154] S. Hohnloser,et al. Prevention of stroke in patients with atrial fibrillation: Current strategies and future directions , 2008 .
[155] D. Singer,et al. Gender Differences in the Risk of Ischemic Stroke and Peripheral Embolism in Atrial Fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) Study , 2005, Circulation.
[156] M. Aguilar,et al. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. , 2005, The Cochrane database of systematic reviews.
[157] J. McMurray,et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. , 2005, Journal of the American College of Cardiology.
[158] R. Bergemann,et al. Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German Experience With Low-Intensity Anticoagulation Study. , 2005, Chest.
[159] D. Parish,et al. Obesity and the risk of new-onset atrial fibrillation. , 2005, JAMA.
[160] G. Lamas,et al. Atrial High Rate Episodes Detected by Pacemaker Diagnostics Predict Death and Stroke: Report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST) , 2003, Circulation.
[161] G. Lip,et al. Antithrombotic therapy for atrial fibrillation , 2002, BMJ : British Medical Journal.
[162] C. M. Hart,et al. Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. , 2002, Journal of the American College of Cardiology.
[163] J. Halperin,et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. , 2001, The New England journal of medicine.
[164] J. Thomas,et al. Efficacy of anticoagulation in resolving left atrial and left atrial appendage thrombi: A transesophageal echocardiographic study. , 2000, American heart journal.
[165] K A Schulman,et al. Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. , 2000, Circulation.
[166] L. Køber,et al. The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. , 1999, European heart journal.
[167] M. Ezekowitz,et al. Initiating and Maintaining Patients on Warfarin Anticoagulation: The Importance of Monitoring , 1999, Journal of cardiovascular pharmacology and therapeutics.
[168] J. Wootton. Clinical practice guidelines. , 1999, Journal of women's health & gender-based medicine.
[169] R. Califf,et al. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. , 1997, Journal of the American College of Cardiology.
[170] B. Iung,et al. AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. , 1996, Circulation.
[171] J. Vandenbroucke,et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. , 1995, The New England journal of medicine.
[172] V. Fuster,et al. Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association. , 1994, Circulation.
[173] U. Goldbourt,et al. Long-term prognosis of patients with paroxysmal atrial fibrillation complicating acute myocardial infarction , 1992 .
[174] U. Goldbourt,et al. Long-term prognosis of patients with paroxysmal atrial fibrillation complicating acute myocardial infarction. SPRINT Study Group. , 1992, European heart journal.
[175] J. Alpert,et al. Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective. , 1990, American heart journal.
[176] G. Bennett,et al. The assessment. , 1989, Health visitor.
[177] J. G. Sharnoff. Prevention of thromboembolism. , 1963 .